Table 5.
Adjusted* hazard ratio (95% confidence interval) for end-stage renal disease, by estimated GFR category
| Estimated glomerular filtration rate (mL/min/1.73 m2) | ||||
|---|---|---|---|---|
| 45–74 | 30–44 | 15–29 | <15 | |
|
Studies with Albumin:Creatinine Ratio
| ||||
| British Columbia | 1.0 (reference) | 1.90 (1.54, 2.35) | 8.34 (6.90, 10.07) | 25.97 (21.24, 31.75) |
| MASTERPLAN | 1.0 (reference) | 2.51 (0.28, 22.51) | 40.66 (5.57, 296.57) | 203.60 (25.68, 1614.08) |
| NephroTest | 1.0 (reference) | 3.75 (1.41, 9.96) | 14.67 (5.88, 36.61) | 75.80 (29.73, 193.26) |
| RENAAL | 1.0 (reference) | 2.66 (1.85, 3.82) | 9.33 (6.50, 13.40) | - |
| Steno | 1.0 (reference) | 4.17 (1.89, 9.18) | 13.08 (6.05, 28.28) | 156.93 (34.44, 715.10) |
|
| ||||
|
Studies with Protein:Creatinine Ratio
| ||||
| AASK | 1.0 (reference) | 3.49 (2.49, 4.88) | 12.24 (8.88, 17.02) | 118.85 (27.53, 513.09) |
| MDRD | 1.0 (reference) | 2.68 (1.92, 3.73) | 6.75 (4.87, 9.34) | 27.35 (17.85, 41.90) |
| MMKD | 1.0 (reference) | 9.34 (2.10, 41.52) | 21.25 (5.01, 90.05) | 121.44 (28.12, 524.42) |
| REIN | 1.0 (reference) | 3.69 (1.67, 8.14) | 11.13 (5.27, 23.49) | 63.43 (20.61, 195.19) |
| REIN 2 | 1.0 (reference) | 1.44 (0.30, 6.91) | 8.59 (2.06, 35.85) | 27.37 (6.22, 120.48) |
|
| ||||
|
Studies with Dipstick Proteinuria
| ||||
| Kaiser Permanente Northwest | 1.0 (reference) | 2.14 (1.29, 3.55) | 15.08 (9.24, 14.60) | - |
|
| ||||
| OVERALL | 1.0 (reference) | 2.72 (2.19, 3.37) | 10.21 (8.36, 12.46) | 51.48 (31.95, 82.97) |
Adjusted for age, sex, race, prior cardiovascular disease, smoking status, diabetes mellitus, systolic blood pressure, and serum total cholesterol concentration.
AASK: African American Study of Kidney Disease and Hypertension; CRIB: Chronic Renal Impairment in Birmingham; MASTERPLAN: Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practicioner; MDRD: Modification of Diet in Renal Disease; MMKD: Mild to Moderate Kidney Disease Study; REIN: Ramipril Efficacy in Nephropathy; REIN 2: Ramipril Efficacy in Nephropathy 2; RENAAL: Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan; Steno: Steno Type 1 Diabetes Study